Key Points
- Director Bros. Advisors Lp Baker bought 2,005,813 shares of Kymera Therapeutics at $86.00 each (about $172.5M), increasing their stake to 7,955,916 shares — a 33.71% rise in ownership disclosed in an SEC filing.
- Despite the insider buy, Kymera last reported a weak quarter (EPS -$0.90 vs. -$0.71 expected; revenue $2.76M vs. $23.15M expected) and remains unprofitable with a negative net margin and projected -2.79 EPS for the year.
- Broker sentiment is generally positive with multiple price-target raises and an average analyst rating of "Buy" and an average price target of $112.80, though a few firms remain bearish.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bros. Advisors Lp Baker acquired 2,005,813 shares of Kymera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $86.00 per share, with a total value of $172,499,918.00. Following the completion of the purchase, the director owned 7,955,916 shares of the company's stock, valued at approximately $684,208,776. The trade was a 33.71% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kymera Therapeutics Stock Down 2.3%
Shares of NASDAQ KYMR opened at $87.81 on Friday. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $103.00. The business's 50 day moving average price is $64.14 and its 200 day moving average price is $51.43. The firm has a market cap of $6.32 billion, a P/E ratio of -24.46 and a beta of 2.28.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.71) by ($0.19). The business had revenue of $2.76 million for the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. As a group, research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. US Bancorp DE lifted its position in shares of Kymera Therapeutics by 9.8% during the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company's stock valued at $106,000 after buying an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Kymera Therapeutics by 9.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company's stock valued at $156,000 after purchasing an additional 248 shares during the period. Larson Financial Group LLC grew its position in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after purchasing an additional 349 shares during the period. Farther Finance Advisors LLC increased its stake in shares of Kymera Therapeutics by 642.9% during the second quarter. Farther Finance Advisors LLC now owns 624 shares of the company's stock worth $27,000 after purchasing an additional 540 shares in the last quarter. Finally, Comerica Bank raised its position in shares of Kymera Therapeutics by 3.6% during the 1st quarter. Comerica Bank now owns 21,374 shares of the company's stock worth $585,000 after purchasing an additional 743 shares during the last quarter.
Analyst Upgrades and Downgrades
Several brokerages have weighed in on KYMR. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Wednesday, October 8th. UBS Group raised Kymera Therapeutics to a "strong-buy" rating in a report on Thursday, December 4th. Mizuho boosted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday. B. Riley raised their price objective on shares of Kymera Therapeutics from $60.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, October 24th. Finally, Barclays lifted their target price on shares of Kymera Therapeutics from $70.00 to $119.00 and gave the company an "overweight" rating in a report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $112.80.
Read Our Latest Report on KYMR
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
